Growth Metrics

Castle Biosciences (CSTL) Income from Continuing Operations (2018 - 2025)

Historic Income from Continuing Operations for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$501000.0.

  • Castle Biosciences' Income from Continuing Operations fell 12208.02% to -$501000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.2 million, marking a year-over-year decrease of 30085.6%. This contributed to the annual value of $18.2 million for FY2024, which is 13174.92% up from last year.
  • Per Castle Biosciences' latest filing, its Income from Continuing Operations stood at -$501000.0 for Q3 2025, which was down 12208.02% from $4.6 million recorded in Q2 2025.
  • Castle Biosciences' Income from Continuing Operations' 5-year high stood at $9.6 million during Q4 2024, with a 5-year trough of -$29.2 million in Q1 2023.
  • In the last 5 years, Castle Biosciences' Income from Continuing Operations had a median value of -$6.4 million in 2021 and averaged -$8.4 million.
  • In the last 5 years, Castle Biosciences' Income from Continuing Operations plummeted by 103938.11% in 2023 and then soared by 47170.54% in 2024.
  • Quarter analysis of 5 years shows Castle Biosciences' Income from Continuing Operations stood at -$6.4 million in 2021, then plummeted by 220.65% to -$20.6 million in 2022, then soared by 87.49% to -$2.6 million in 2023, then surged by 471.71% to $9.6 million in 2024, then tumbled by 105.22% to -$501000.0 in 2025.
  • Its last three reported values are -$501000.0 in Q3 2025, $4.6 million for Q2 2025, and -$25.8 million during Q1 2025.